Operating CF
$715.30M
Capex
−$257.30M
Free Cash Flow
$458.00M
FCF Margin
+64.0%
Cash flow waterfall for West Pharmaceutical Services (WST) — TTM through Q1 2026
Free cash flow: $458.00M
Cash flow breakdown for West Pharmaceutical Services (WST) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $715.30M | $715.30M |
| Capital Expenditure | −$257.30M | $458.00M |
| Free Cash Flow | $458.00M | $458.00M |
| Share Buybacks | −$298.40M | $159.60M |
| Dividends Paid | −$61.80M | $97.80M |
| Other Financing & FX | $19.40M | $117.20M |
| Net Cash Increase | $117.20M | $117.20M |
- Operating Cash Flow$715.30M
- Capital Expenditure−$257.30M
- Free Cash Flow$458.00M
- Share Buybacks−$298.40M
- Dividends Paid−$61.80M
- Other Financing & FX$19.40M
- Net Cash Increase$117.20M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
West Pharmaceutical Services (WST) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement